Arrhythmia, Cryoablation, Desflurane, General Anesthesia, Remimazolam
Conditions
Keywords
Remimazolam, Desflurane, Arrhythmia, Cryoablation,heart, Cardiovascular disease
Brief summary
In anesthesia for ablation for cardiac arrhythmias, abrupt hemodynamic changes or fatal arrhythmias can be seen frequently. Remimazolam is a novel ultra-short acting benzodiazepine that provides good hemodynamic stability compared to conventional anesthetic agents. This study aims to investigate whether remimazolam reduces vasoactive agent use during cryo/radiofrequancy ablation under general anesthesia, compared to desflurane(RCT).
Interventions
DRUGRemimazolam besylate
Remimazolam besylate TIVA
Sponsors
Seoul National University Bundang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
ALL
Age
20 Years to 105 Years
Healthy volunteers
No
Inclusion criteria
* =or \> 20 years * Admission for General anesthesia for RFCA or cryoablation procedure
Exclusion criteria
* No severe adverse effect history or hypersensitivity of benzodiazepines or its additives * Acute alcoholic intoxication state * Coma or shock state due to other condition than heart problem. * Acute narrow-angle glaucoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hypotension event | During and after anesthesia | Hypotension event |
| Vasopressor (total amount) | During anesthesia | Norepinephrine equivalent dose |
| Vasopressor CIV | During anesthesia | Vasopressor CIV or not |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Induction time | Induction | Induction dose administration\ LOC |
| Recovery time | Recovery | Reversal agent administration\ extubation |
| Adverse event | During and after anesthesia (~24hr) | Adverse event (desaturation, vomiting, hypotension, bleeding, allergic or anaphylaxis, etc.) |
Countries
South Korea
Outcome results
None listed